跳至主要内容
临床试验/NCT05256394
NCT05256394已完成不适用

Scaling Interoperable Clinical Decision Support for Patient-Centered Chronic Pain Care

University of Florida2 个研究点 分布在 1 个国家目标入组 39 人开始时间: 2025年1月13日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
39
试验地点
2
主要终点
Adoption

研究概览

简要总结

This study will adapt and scale existing AHRQ-supported interoperable CDS for patient-centered chronic pain care. The objective of this project is to study the adaptation and implementation of an existing interoperable CDS tool for pain treatment shared decision making, with tailored implementation support, in primary care clinical settings. The central hypothesis is that tailored implementation support will increase CDS adoption and shared decision making.

详细描述

This study will adapt and scale the use of existing AHRQ-supported interoperable CDS that aids patient-centered chronic pain treatment decision making. The research will generate critical evidence on scalable strategies to implement and evaluate interoperable CDS in real-world settings across different types of EHRs. The pragmatic trial will enhance the reach of interoperable CDS to more diverse populations. Together, these efforts will lead to important new technology and evidence that patients, clinicians, and health systems can use to improve care for millions of Americans who suffer from pain and other chronic conditions.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Health Services Research
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Primary care patients receiving care at a participating clinic
  • Patients with chronic non-cancer musculoskeletal pain and with a recent history of opioid use

排除标准

  • Due to the fact that the clinical decision support tool is currently available in English only, non-English speaking patients will not be eligible to participate

结局指标

主要结局

Adoption

时间窗: During the implementation trial (5 months total)

Rate of qualifying patients seen for whom CDS use is documented

次要结局

  • Reach(During the implementation trial (5 months total))
  • Shared decision making(Immediately after the intervention)
  • Pain and function(Baseline/pre-intervention, and at 1 and 3 months)
  • Any opioid prescription(Baseline/pre-intervention, and at 1 and 3 months)
  • Opioid prescriptions ≥50 MME/day(Baseline/pre-intervention, and at 1 and 3 months)
  • Opioid prescriptions ≥90 MME/day(Baseline/pre-intervention, and at 1 and 3 months)
  • Benzodiazepine prescription concurrent with opioid prescription(Baseline/pre-intervention, and at 1 and 3 months)
  • Prescriptions for non-opioid pain medications(Baseline/pre-intervention, and at 1 and 3 months)
  • Prescriptions for non-pharmacologic pain treatments(Baseline/pre-intervention, and at 1 and 3 months)
  • Urine drug screen orders(Baseline/pre-intervention, and at 1 and 3 months)
  • Naloxone prescriptions(Baseline/pre-intervention, and at 1 and 3 months)
  • Prescription or referral for medication-assisted therapy (MAT)(Baseline/pre-intervention, and at 1 and 3 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验